The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing

Although the only effective drug against primary hepatocarcinoma, the multikinase inhibitor Sorafenib (SFB) usually fails to eradicate liver cancer. Since SFB targets mitochondria, cell metabolic reprogramming may underlie intrinsic tumor resistance. To characterize cancer cell metabolic response to...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Sci Rep
मुख्य लेखकों: Tesori, Valentina, Piscaglia, Anna Chiara, Samengo, Daniela, Barba, Marta, Bernardini, Camilla, Scatena, Roberto, Pontoglio, Alessandro, Castellini, Laura, Spelbrink, Johannes N., Maulucci, Giuseppe, Puglisi, Maria Ausiliatrice, Pani, Giovambattista, Gasbarrini, Antonio
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group 2015
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4361992/
https://ncbi.nlm.nih.gov/pubmed/25779766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep09149
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन